HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study.

摘要: We used real-time quantitative polymerase chain reaction (rqPCR) to detect human epidermal growth factor receptor 2 (HER2) amplification in the circulating cell-free DNA (cfDNA) of patients with gastric cancer (GC), which shows spatial and temporal intrinsic heterogeneity HER2 expression/copy number during progression, for liquid biopsy treatment monitoring. first enrolled 52 advanced GC who underwent surgery 40 healthy volunteers. For GC, plasma cfDNA was obtained before (43 patients) postoperative (nine 43 patients). After ribonuclease P RNA component H1 (RPPH1) had been selected as a reference gene CN assessment by rqPCR tumours plasma, HER2-to-RPPH1 ratios were determined retrospectively development cohort an additional independent validation cohort. The ratio tissues concordant routinely status. significantly higher HER2-positive than those HER2-negative tumours. sensitivity specificity test 0.539 0.967, respectively, cohort, 0.667 1.000, amplifications acquired lost tumour progression treatment, apparently detected repeated assessments treatment. Our preliminary data demonstrated potential clinical use therapeutic marker monitor status effective molecular targeted therapy GC.